Biopharmaceutical research companies are developing 465 medicines and vaccines for the 10 leading chronic diseases affecting Medicare beneficiaries.* This report lists medicines and vaccines in human clinical trials or under review by the U.S. Food and Drug Administration (FDA).

1. 2013 REPORT
Medicines in Development
Older Americans
The Medicare Population and Leading Chronic Diseases
presented by america’s biopharmaceutical research companies
More Than 400 Medicines in Development for
Leading Chronic Diseases Affecting Older Americans
CHRONIC KIDNEY DISEASE COPD CHRONIC KIDNEY DISEASE
CATARACTS
DEMENTIA
RHEUMATOID ARTHRITIS
COPD ISCHEMIC HEART DISEASE ALZHEIMER'S DISEASE
40
DEPRESSION OSTEOARTHRITIS HEART FAILURE
OSTEOPOROSIS
Medicines in Development MORE MILLION DIABETES
For Leading Chronic
THAN MEDICARE RECIPIENTS
90
Diseases Affecting Seniors
CATARACTS
ALZHEIMER'S
DEMENTIA
DIABETES
OSTEOPOROSIS
PERCENT OF ALL
Application
Submitted
142
DEPRESSION
RHEUMATOID ARTHRITIS
BENEFICIARIES
Phase III
HAVE PRESCRIPTION DRUG COVERAGE
Phase II
Biopharmaceutical research companies • 0 for chronic kidney disease, where
2
are developing 465 medicines and vac- prevalence grows with older age.
Phase I
cines for the 10 leading chronic diseases • 5 for osteoporosis, a major health
1
affecting Medicare beneficiaries.* This threat for an estimated 44 million
report lists medicines and vaccines in Americans.
92 human clinical trials or under review by
the U.S. Food and Drug Administration Definitions for selected terms can be
82 (FDA). found on page 36. A link to the sponsor
company’s web site provides more de-
The medicines in development include: tailed information on the science behind
• 42 for diabetes, which affects 10.9
1 each potential product.
million Americans age 65 and older. For information on the value of medicines,
9
• 2 for rheumatoid arthritis and osteo- an in-depth look at current innovation
arthritis, which affects 12.4 million and key medical breakthroughs benefit-
48 people, age 65 and older. ing older Americans, please see Medi-
40 8
• 2 for Alzheimer’s disease, which cines in Development for Older Ameri-
34 could afflict nearly 8 million people by cans 2013—Overview.
2030 unless a cure or prevention is The medicines in this report provide hope
found. to older Americans who suffer from these
4
• 8 for heart failure and ischemic heart debilitating chronic diseases and are
disease, two of many cardiovascular dis- seeking to live longer, more independent
eases affecting 80.7 million Americans, and healthier lives.
half of which are age 60 and older.
• 0 for COPD, which affects Americans
4
over age 65 at a higher rate.
’s
PD
s
e
s
ion
ete
as
riti
er
CO
s
eim
ise
• 4 for depression, which affects an
3
th
ab
es
Ar
tD
Di
pr
zh
estimated 6.5 million Americans age
De
ar
Al
65 and older.
He
*Centers for Medicare and Medicaid Services (CMS), Chronic Condition Data Warehouse (CCW) Medicare 5% Sample, 2009

2. Medicines in Development for Older Americans
Alzheimer’s Disease and Dementia
Product Name Sponsor Indication Development Phase*
18F-florbetaben Piramal Healthcare Alzheimer’s disease (diagnosis) Phase III
(BAY 94-9172) Mumbai, India piramalenterprises.com
AAB-003/PF-05236812 Janssen Alzheimer Immunotherapy Alzheimer’s disease Phase I
(amyloid beta protein inhibitor) South San Francisco, CA janimm.com
Pfizer pfizer.com
New York, NY
ABT-126 AbbVie mild to moderate Alzheimer’s Phase II
(α7-NNR antagonist) North Chicago, IL disease abbvie.com
ABT-288 AbbVie Alzheimer’s disease Phase II completed
(neurotransmitter receptor North Chicago, IL abbvie.com
modulator)
ABT-384 AbbVie Alzheimer’s disease Phase II completed
North Chicago, IL abbvie.com
ABT-957 AbbVie Alzheimer’s disease Phase I
(calpain inhibitor) North Chicago, IL abbvie.com
AC-1204 Accera Alzheimer’s disease Phase II/III
Broomfield, CO accerapharma.com
ACC-001/PF-05236806 Janssen Alzheimer Immunotherapy Alzheimer’s disease Phase II
South San Francisco, CA janimm.com
Pfizer pfizer.com
New York, NY
AD02 vaccine Affiris treatment of Alzheimer’s disease Phase II
Vienna, Austria gsk.com
GlaxoSmithKline
Rsch. Triangle Park, NC
AD03 vaccine Affiris treatment of Alzheimer’s disease Phase I
Vienna, Austria gsk.com
GlaxoSmithKline
Rsch. Triangle Park, NC
AD4833/TOMM40 Takeda Pharmaceuticals International Alzheimer’s disease prevention Phase I
Deerfield, IL takeda.com
APH-0703 Aphios Alzheimer’s disease Phase I/II
(protein kinase C activator) Woburn, MA aphios.com
*For more information about a specific medicine or company in the report, please click on the provided link.
2 Medicines in Development Older Americans 2013

3. Medicines in Development for Older Americans
Alzheimer’s Disease and Dementia
Product Name Sponsor Indication Development Phase
ARC029 Archer Pharmaceuticals Alzheimer’s disease Phase I
(nilvadipine) Sarasota, FL archerpharma.com
ARC031 Archer Pharmaceuticals Alzheimer’s disease Phase I
(soluble amyloid reducing/clearing Sarasota, FL archerpharma.com
agent)
ARC031 SR Archer Pharmaceuticals Alzheimer’s disease Phase I
(soluble amyloid reducing/clearing Sarasota, FL archerpharma.com
agent)
AVN 101 Avineuro Pharmaceuticals Alzheimer’s disease Phase II
(serotonin 5-HT6 receptor San Diego, CA avineuro.com
antagonist)
AVN 322 Avineuro Pharmaceuticals Alzheimer’s disease Phase I
(serotonin 5-HT6 receptor San Diego, CA avineuro.com
antagonist)
AVN 397 Avineuro Pharmaceuticals Alzheimer’s disease Phase II
San Diego, CA avineuro.com
AZD1446 AstraZeneca Alzheimer’s disease Phase I
(alpha4/beta2 neuronal nicotinic Wilmington, DE astrazeneca.com
receptor agonist) Targacept
Winston-Salem, NC
AZD2184 Navidea Biopharmaceuticals Alzheimer’s disease (diagnosis) Phase I
(PET imaging) Dublin, OH navidea.com
AZD2995 Navidea Biopharmaceuticals Alzheimer’s disease (diagnosis) Phase I
(PET imaging) Dublin, OH navidea.com
AZD3293 AstraZeneca Alzheimer’s disease Phase I
(beta secretase) Wilmington, DE astrazeneca.com
Astex Pharmaceuticals
Dublin, CA
AZD5213 AstraZeneca Alzheimer’s disease Phase II
(histamine-3 receptor antagonist) Wilmington, DE astrazeneca.com
ß-secretase inhibitor Eli Lilly Alzheimer’s disease Phase II
(LY2886721) Indianapolis, IN (slow disease progression) lilly.com
BAN2401 Eisai early-stage Alzheimer’s disease Phase II
Woodcliff Lake, NJ eisai.com
BAY 85-8101 Piramal Healthcare Alzheimer’s disease (diagnosis) Phase I completed
(18F-labeled radiopharmaceutical) Mumbai, India piramalenterprises.com
Medicines in Development Older Americans 2013 3

4. Medicines in Development for Older Americans
Alzheimer’s Disease and Dementia
Product Name Sponsor Indication Development Phase
BIIB037 Biogen Idec Alzheimer’s disease Phase I
(anti-ß-amyloid antibody) Weston, MA biogenidec.com
bisnorcymserine QR Pharma Alzheimer’s disease Phase I
(BNC) Berwyn, PA qrpharma.com
BMS-241027 Bristol-Myers Squibb Alzheimer’s disease, Phase I
(microtubule stabilizer) Princeton, NJ senile dementia bms.com
CAD106 Novartis Pharmaceuticals Alzheimer’s disease Phase II
East Hanover, NJ novartis.com
CERE-110 Ceregene Alzheimer’s disease Phase II
(AAV-NGF gene therapy) San Diego, CA ceregene.com
crenezumab Genentech Alzheimer’s disease Phase II
(anti-Abeta) South San Francisco, CA gene.com
davunetide intranasal Allon Therapeutics Alzheimer’s disease Phase II
Vancouver, Canada allontherapeutics.com
donepezil/memantine Adamas Pharmaceuticals moderate to severe Alzheimer’s Phase II
extended-release fixed-dose Emeryville, CA disease adamaspharma.com
combination Forest Laboratories frx.com
New York, NY
DSP-8658 Sunovion Pharmaceuticals Alzheimer’s disease Phase I
(PPAR alpha/gamma agonist) Marlborough, MA (see also diabetes) sunovion.com
E2609 Eisai Alzheimer’s disease Phase I completed
Woodcliff Lake, NJ eisai.com
ELND005 Elan Alzheimer’s disease Phase II
(amyloid beta-protein inhibitor) Dublin, Ireland elan.com
EVP-0962 EnVivo Pharmaceuticals Alzheimer’s disease Phase II
(gamma secretase modulation) Watertown, MA envivopharma.com
EVP-6124 EnVivo Pharmaceuticals Alzheimer’s disease Phase II
(nicotine A7 agonist) Watertown, MA envivopharma.com
Exebryl-1® ProteoTech Alzheimer’s disease Phase I
Alzheimer’s disease therapeutic Kirkland, WA proteotech.com
F-18 T808 Siemens Molecular Imaging Alzheimer’s disease (diagnosis) Phase 0
(PET imaging agent) Malvern, PA medical.siemens.com
F18-flutemetamol GE Healthcare Alzheimer’s disease (diagnosis) application submitted
(PET imaging agent) Waukesha, WI gehealthcare.com
4 Medicines in Development Older Americans 2013

5. Medicines in Development for Older Americans
Alzheimer’s Disease and Dementia
Product Name Sponsor Indication Development Phase
Gammagard® Baxter International early-stage Alzheimer’s disease, Phase III
immune globulin Deerfield, IL mid-stage Alzheimer’s disease baxter.com
gamma secretase modulator, Bristol-Myers Squibb Alzheimer’s disease, in clinical trials
A-beta modulator Princeton, NJ senile dementia bms.com
gantenerumab Roche early-stage Alzheimer’s disease Phase II/III
(amyloid beta-protein inhibitor) Nutley, NJ roche.com
GSK742457 GlaxoSmithKline dementia Phase II
(5-HT6 receptor antagonist) Rsch. Triangle Park, NC gsk.com
GSK2647544 GlaxoSmithKline Alzheimer’s disease Phase I
(Lp-PLA2 inhibitor) Rsch. Triangle Park, NC gsk.com
HPP 854 High Point Pharmaceuticals Alzheimer’s disease Phase I
(BACE1 protein inhibitor) High Point, NC highpointpharma.com
human immunoglobulin Grifols Alzheimer’s disease Phase III
(intravenous) Los Angeles, CA grifols.com
KU-046 Kareus Therapeutics Alzheimer’s disease Phase I
(amyloid-ß protein modulator) La Chaux-de-Fonds, Switzerland kareustherapeutics.com
Lu AE58054 Lundbeck USA Alzheimer’s disease Phase II
Deerfield, IL lundbeck.com
masitinib AB Science USA Alzheimer’s disease Phase III completed
(AB-1010) Short Hills, NJ ab-science.com
MCD-386 Mithridion Alzheimer’s disease Phase I
Madison, WI mithridion.com
MK-3328 Merck Alzheimer’s disease (diagnosis) Phase I completed
(PET imaging) Whitehouse Station, NJ merck.com
MK-8931 Merck Alzheimer’s disease Phase II/III
(BACE1 protein inhibitor) Whitehouse Station, NJ merck.com
MSDC-0160 Metabolic Solutions Development Alzheimer’s disease Phase II
Kalamazoo, MI (see also diabetes) msdrx.com
NAV4694 Navidea Biopharmaceuticals Alzheimer’s disease (diagnosis) Phase III
(fluorine-18 labeled PET Dublin, OH navidea.com
imaging agent)
NIC5-15 Humanetics Alzheimer’s disease Phase II
Minneapolis, MN humaneticscorp.com
Medicines in Development Older Americans 2013 5

6. Medicines in Development for Older Americans
Alzheimer’s Disease and Dementia
Product Name Sponsor Indication Development Phase
PF-05212377 Pfizer Alzheimer’s disease Phase II
(SAM-760) New York, NY pfizer.com
Posiphen® QR Pharma Alzheimer’s disease, Phase II
R-phenserine Berwyn, PA mild cognitive impairment qrpharma.com
PRX-3140 Nanotherapeutics Alzheimer’s disease Phase II
(serotonin 4 receptor agonist) Alachua, FL nanotherapeutics.com
RG1577 Roche Alzheimer’s disease Phase II
(MAO-B inhibitor) Nutley, NJ roche.com
RG7129 Roche Alzheimer’s disease Phase I
(BACE-1 inhibitor) Nutley, NJ roche.com
rilapladib GlaxoSmithKline Alzheimer’s disease Phase II
(Lp-PLA2 inhibitor) Rsch. Triangle Park, NC gsk.com
RVX-208 Resverlogix Alzheimer’s disease Phase I
Calgary, Canada resverlogix.com
SAR110894 Sanofi US Alzheimer’s disease Phase II
(H3 antagonist) Bridgewater, NJ sanofi.com
SAR228810 Sanofi US Alzheimer’s disease Phase I
(anti-protofibrillar AB mAb) Bridgewater, NJ sanofi.com
sGC-1061 sGC Pharma Alzheimer’s disease Phase I
Wellesley, MA sgcpharma.com
solanezumab Eli Lilly Alzheimer’s disease Phase III
(LY2062430) Indianapolis, IN lilly.com
ST101 Sonexa Therapeutics Alzheimer’s disease Phase II
San Diego, CA sonexa.com
T-817MA Toyota Chemical mild to moderate Alzheimer’s Phase II completed
(amyloid beta-protein inhibitor) Tokyo, Japan disease toyama-chemical.co.jp
TAK-357 Takeda Pharmaceuticals International Alzheimer’s disease Phase I
(oral cognitive enhancer) Deerfield, IL takeda.com
TC-1734 Targacept Alzheimer’s disease Phase II
(alpha4/beta2 neuronal nicotinic Winston-Salem, NC targacept.com
receptor agonist)
TC-5619 Targacept Alzheimer’s disease Phase I
(alpha7 nAChR) Winston-Salem, NC targacept.com
6 Medicines in Development Older Americans 2013

7. Medicines in Development for Older Americans
Alzheimer’s Disease and Dementia
Product Name Sponsor Indication Development Phase
TRx-0237 TauRx Therapeutics Alzheimer’s disease, dementia Phase III
(LMTX) Singapore, Republic of Singapore taurx.com
TTP4000 TransTech Pharma Alzheimer’s disease Phase I
High Point, NC ttpharma.com
TTP488 TransTech Pharma Alzheimer’s disease Phase II
High Point, NC ttpharma.com
UB-311 United Biomedical mild to moderate Alzheimer’s Phase I
(amyloid beta protein inhibitor Hauppauge, NY disease unitedbiomedical.com
vaccine)
V950 Merck Alzheimer’s disease Phase I
Whitehouse Station, NJ merck.com
velusetrag Theravance Alzheimer’s disease Phase I completed
(TD-5108) South San Francisco, CA theravance.com
VI-1121 VIVUS Alzheimer’s disease Phase II
Mountain View, CA vivus.com
XEL-001HP Xel Pharmaceuticals Alzheimer’s disease Phase I
(transdermal patch) Draper, UT xelpharmaceuticals.com
Arthritis
Product Name Sponsor Indication Development Phase
2ME2 EntreMed rheumatoid arthritis Phase I
Rockville, MD entremed.com
ABT-122 AbbVie rheumatoid arthritis Phase I
(anti-TNF/anti-IL-17 mAb) North Chicago, IL abbvie.com
ABT-413 AbbVie rheumatoid arthritis Phase I
(sphingosine 1 phosphate receptor North Chicago, IL abbvie.com
modulator)
ABT-494 AbbVie rheumatoid arthritis Phase I
(JAK-1, 2, 3 inhibitor) North Chicago, IL abbvie.com
Medicines in Development Older Americans 2013 7

8. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
ABT-652 AbbVie osteoarthritis of the knee Phase II
(histamine H3 receptor modulator) North Chicago, IL abbvie.com
ABT-981 AbbVie osteoarthritis Phase I
(anti-IL-1 α and β mAb) North Chicago, IL abbvie.com
Actemra® Genentech rheumatoid arthritis application submitted
tocilizumab South San Francisco, CA (first-line therapy) gene.com
Roche roche.com
Nutley, NJ -------------------------------------- -----------------------------------------
rheumatoid arthritis Phase III
(early-stage disease) gene.com
roche.com
adalimumab biosimilar Boehringer Ingelheim Pharmaceuticals rheumatoid arthritis Phase I completed
Ridgefield, CT boehringer-ingelheim.com
AF-219 Afferent Pharmaceuticals osteoarthritis Phase II
(purinoceptor P2X3 antagonist) San Mateo, CA afferentpharma.com
AIN457 Novartis Pharmaceuticals rheumatoid arthritis Phase III
(secukinumab) East Hanover, NJ novartis.com
ARG301 arGentis Pharmaceuticals rheumatoid arthritis Phase I
Memphis, TN argentisrx.com
ARRY-797 Array BioPharma moderate to severe pain associated Phase II
(p38 MAPK inhibitor) Boulder, CO with osteoarthritis of the knee arraybiopharma.com
ASP015K Astellas Pharma US rheumatoid arthritis Phase II
(JAK-3 inhibitor) Northbrook, IL astellas.com
ASP2408 Perseid Therapeutics rheumatoid arthritis Phase I
(CTLA4-Ig fusion protein) Redwood City, CA perseidtherapeutics.com
baricitinib Eli Lilly rheumatoid arthritis Phase III
(LY3009104) Indianapolis, IN (see also chronic kidney) lilly.com
BI-695500 Boehringer Ingelheim Pharmaceuticals rheumatoid arthritis Phase III
(rituximab biosimilar) Ridgefield, CT boehringer-ingelheim.com
BMS-817399 Bristol-Myers Squibb osteoarthritis, Phase II
(CCR1 antagonist) Princeton, NJ rheumatoid arthritis bms.com
BT-061 AbbVie rheumatoid arthritis Phase II
North Chicago, IL abbvie.com
Biotest biotest.de
Dreieich, Germany
8 Medicines in Development Older Americans 2013

9. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
buprenorphine transmucosal BioDelivery Sciences International chronic pain associated with Phase III
Raleigh, NC osteoarthritis bdsi.com
Endo Pharmaceuticals endo.com
Malvern, PA
canakinumab Novartis Pharmaceuticals gouty arthritis application submitted
(ACZ885) East Hanover, NJ (see also diabetes) novartis.com
-------------------------------------- -----------------------------------------
osteoarthritis Phase II
novartis.com
cebranopadol Forest Laboratories pain due to osteoarthritis of the Phase II
New York, NY knee frx.com
CEP-33237 Cephalon osteoarthritis pain Phase III
(hydrocodone extended-release) Frazer, PA cephalon.com
CF101 Can-Fite BioPharma rheumatoid arthritis Phase II
Waltham, MA canfite.com
Chondrogen™ Osiris Therapeutics osteoarthritis (prevention) Phase II
mesenchymal stem cell therapy Columbia, MD osiris.com
Cimzia® UCB early rheumatoid arthritis Phase III
certolizumab pegol Smyrna, GA ucb.com
clazakizumab Bristol-Myers Squibb osteoarthritis, Phase II
(anti-IL6-mAb) Princeton, NJ rheumatoid arthritis bms.com
CNTO-1959 Janssen Biotech rheumatoid arthritis Phase II
Horsham, PA janssenbiotech.com
COV-155 Mallinckrodt osteoarthritis Phase III
Hazelwood, MO mallinckrodt.com
COV-795 Mallinckrodt osteoarthritis Phase III
Hazelwood, MO mallinckrodt.com
CT-1578 Cell Therapeutics rheumatoid arthritis Phase I
(JAK2/FLT-3/c-Fms inhibitor) Seattle, WA celltherapeutics.com
Dekavil Pfizer rheumatoid arthritis Phase I
(F8-IL10) New York, NY pfizer.com
Philogen philogen.com
Sovicille, Italy
DMI-9523 Ampio Pharmaceuticals osteoarthritis Phase I
Greenwood Village, CO ampiopharma.com
Medicines in Development Older Americans 2013 9

10. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
etoricoxib Merck rheumatoid arthritis Phase III
Whitehouse Station, NJ merck.com
fostamatinib AstraZeneca rheumatoid arthritis Phase III
(SYK inhibitor) Wilmington, DE astrazeneca.com
Rigel Pharmaceuticals rigel.com
South San Francisco, CA
FX005 Flexion Therapeutics osteoarthritis of the knee Phase I/II
(p38 MAPK inhibitor) Woburn, MA flexiontherapeutics.com
FX006 Flexion Therapeutics osteoarthritis of the knee Phase II
(triamcinolone acetonide Woburn, MA flexiontherapeutics.com
intra-articular sustained-release)
gevokizumab XOMA osteoarthritis of the hand Phase II
(XOMA 052) Berkeley, CA xoma.com
GLPG-0555 Galapagos osteoarthritis Phase I
Mechelen, Belgium gsk.com
GlaxoSmithKline
Rsch. Triangle Park, NC
GLPG-0634 AbbVie rheumatoid arthritis Phase II
North Chicago, IL abbvie.com
Galapagos
Mechelen, Belgium
GSK2941266 GlaxoSmithKline rheumatoid arthritis Phase II
(CCR1 chemokine receptor Rsch. Triangle Park, NC gsk.com
antagonist)
HE3286 Harbor Biosciences rheumatoid arthritis Phase II
San Diego, CA (see also diabetes) harbortx.com
INCB39110 Incyte active rheumatoid arthritis Phase II
(JAK1 inhibitor) Wilmington, DE incyte.com
IP045 Iroko Pharmaceuticals pain associated with osteoarthritis Phase I
(meloxicam) Philadelphia, PA of the knee iroko.com
IP-880 Iroko Pharmaceuticals osteoarthritis pain Phase III
(low dose diclofenac) Philadelphia, PA iroko.com
10 Medicines in Development Older Americans 2013

11. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
ISIS-CRPRx Isis Pharmaceuticals rheumatoid arthritis Phase II
(C-reactive protein inhibitor) Carlsbad, CA isispharm.com
JNJ-38518168 Janssen Research Development rheumatoid arthritis Phase II
(histamine H4 receptor Raritan, NJ janssenrnd.com
antagonist)
JNJ-39439335 Janssen Research Development chronic pain associated with Phase I
(mavatrep) Raritan, NJ osteoarthritis of the knee janssenrnd.com
JNJ-40346527 Janssen Research Development rheumatoid arthritis Phase II
(M-CSF receptor antagonist) Raritan, NJ janssenrnd.com
LT-NS001 Logical Therapeutics osteoarthritis Phase II/III
(naproxen etemesil) Foxboro, MA logicaltx.com
LX2931 Lexicon Pharmaceuticals rheumatoid arthritis Phase II
(S1P lyase inhibitor) The Woodlands, TX lexicon-genetics.com
mavrilimumab AstraZeneca rheumatoid arthritis Phase II
(anti-GM-CSFR mAb) Wilmington, DE astrazeneca.com
MedImmune medimmune.com
Gaithersburg, MD
MEDI-5117 AstraZeneca rheumatoid arthritis Phase I
(anti-IL-6 mAb) Wilmington, DE astrazeneca.com
MedImmune medimmune.com
Gaithersburg, MD
mesenchymal stem cell therapy for Medipost osteoarthritis Phase I/II
cartilage repair Seoul, South Korea medi-post.com
MK-8457 Merck rheumatoid arthritis Phase II
Whitehouse Station, NJ merck.com
MK-8808 Merck rheumatoid arthritis Phase I
Whitehouse Station, NJ merck.com
MORAb-022 Eisai rheumatoid arthritis Phase I
(IgG1 mAb) Woodcliff Lake, NJ eisai.com
namilumab Takeda Pharmaceuticals International rheumatoid arthritis Phase I
Deerfield, IL takeda.com
naproxcinod NicOx osteoarthritis application submitted
Sophia Antipolis, France nicox.com
Medicines in Development Older Americans 2013 11

12. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
NN8209 Novo Nordisk rheumatoid arthritis Phase II
(anti-C5aR-151) Princeton, NJ novonordisk.com
NN8210 Novo Nordisk rheumatoid arthritis Phase I
(anti-C5aR-215) Princeton, NJ novonordisk.com
NN8226 Novo Nordisk rheumatoid arthritis Phase II
(anti-IL20 mAb) Princeton, NJ novonordisk.com
NN8765 Novo Nordisk rheumatoid arthritis Phase I
(anti-NKG2A) Princeton, NJ novonordisk.com
NN8828 Novo Nordisk rheumatoid arthritis Phase II
(anti-IL21 mAb) Princeton, NJ novonordisk.com
olokizumab UCB rheumatoid arthritis Phase II
Smyrna, GA ucb.com
OLT-1177 Olatec Industries pain associated with osteoarthritis Phase II
New York, NY of the knee
osteoarthritis medicine Eli Lilly osteoarthritis pain Phase I
(NCE) Indianapolis, IN lilly.com
otelixizumab GlaxoSmithKline rheumatoid arthritis Phase I
(CD3 mAb) Rsch. Triangle Park, NC gsk.com
Otrexup™ Antares Pharma rheumatoid arthritis application submitted
methotrexate subcutaneous Ewing, NJ antarespharma.com
auto-injection
ozoralizumab Ablynx rheumatoid arthritis Phase II
Ghent, Belgium ablynx.com
PDA-001 Celgene Cellular Therapeutics rheumatoid arthritis Phase I/II
(stem cell therapy) Summit, NJ celgene.com
Pennsaid® 2% Mallinckrodt osteoarthritis pain and stiffness application submitted
diclofenac transdermal Hazelwood, MO mallinckrodt.com
PF-04171327 Pfizer rheumatoid arthritis Phase II
(SGRM) New York, NY pfizer.com
PF-04236921 Pfizer rheumatoid arthritis Phase I
(mAb) New York, NY pfizer.com
PF-05280586 Pfizer rheumatoid arthritis Phase I
(rituximab biosimilar) New York, NY pfizer.com
12 Medicines in Development Older Americans 2013

13. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
PLX5622 Plexxikon rheumatoid arthritis Phase I
(FGF-1 antagonist) Berkeley, CA plexxikon.com
Prolia® Amgen rheumatoid arthritis Phase II
denosumab Thousand Oaks, CA amgen.com
PRTX-100 Protalex rheumatoid arthritis Phase I
(staphylococcal protein A) Summit, NJ protalex.com
Ravax™ Immune Response BioPharma rheumatoid arthritis Phase III
rheumatoid arthritis vaccine New York, NY immuneresponsebiopharma.com
RX-10001 Resolvyx Pharmaceuticals rheumatoid arthritis Phase I
(synthetic resolvin) Cambridge, MA resolvyx.com
SAN-300 Santarus rhematoid arthritis Phase I
(anti-VLA-1 antibody) San Diego, CA santarus.com
SAR113945 Sanofi US osteoarthritis Phase II
(IKK-ß inhibitor) Bridgewater, NJ sanofi.com
SAR292833 Sanofi US osteoarthritis pain Phase II
(TRVP3 antagonist) Bridgewater, NJ sanofi.com
sarilumab Sanofi US rheumatoid arthritis Phase III
(anti-IL-6R mAb) Bridgewater, NJ sanofi.com
Simponi® Janssen Biotech moderate to severe rheumatoid application submitted
golimumab (intravenous) Horsham, PA arthritis janssenbiotech.com
sirukumab GlaxoSmithKline rheumatoid arthritis Phase III
(anti-IL-6 mAb) Rsch. Triangle Park, NC gsk.com
Janssen Biotech janssenbiotech.com
Horsham, PA
sprifermin EMD Serono osteoarthritis Phase I
(FGF-18) Rockland, MA emdserono.com
TG-C TissueGene osteoarthritis Phase II
(allogeneic cell therapy) Rockville, MD tissuegene.com
Stelara® Janssen Research Development rheumatoid arthritis Phase II
ustekinumab Raritan, NJ janssenrnd.com
Medicines in Development Older Americans 2013 13

14. Medicines in Development for Older Americans
Arthritis
Product Name Sponsor Indication Development Phase
V116517 Purdue Pharma pain associated with osteoarthritis Phase II
Stamford, CT of the knee purduepharma.com
veltuzumab Immunomedics rheumatoid arthritis Phase II
subcutaneous Morris Plains, NJ immunomedics.com
Takeda Pharmaceuticals International takeda.com
Deerfield, IL
VX30 Vaccinex rheumatoid arthritis Phase I
Rochester, NY vaccinex.com
VX-509 Vertex Pharmaceuticals rheumatoid arthritis Phase II
Cambridge, MA vrtx.com
Cataracts
Product Name Sponsor Indication Development Phase
dexamethasone ophthalmic EyeGate Pharma cataracts Phase II
(EGP-437) Waltham, MA eyegatepharma.com
Chronic Kidney Disease
Product Name Sponsor Indication Development Phase
Acthar® Gel Questcor Pharmaceuticals diabetic nephropathy Phase II
corticotropin gel Anaheim Hills, CA questcor.com
atrasentan AbbVie diabetic nephropathy Phase II
North Chicago, IL abbvie.com
AZD1722 Ardelyx chronic kidney disease Phase I
(NHE3 inhibitor) Fremont, CA ardelyx.com
AstraZeneca astrazeneca.com
Wilmington, DE
baricitinib Eli Lilly diabetic nephropathy Phase II
(LY3009104) Indianapolis, IN (see also arthritis) lilly.com
14 Medicines in Development Older Americans 2013

15. Medicines in Development for Older Americans
Chronic Kidney Disease
Product Name Sponsor Indication Development Phase
BB-3 Angion chronic kidney fibrosis Phase I
Uniondale, NY angion.com
BMS-813160 Bristol-Myers Squibb chronic kidney disease Phase I
(dual CCR2/CCR5 antagonist) Princeton, NJ bms.com
CCX140 ChemoCentryx diabetic nephropathy Phase I
(CCR2 receptor antagonist) Mountain View, CA chemocentryx.com
chronic kidney disease therapeutic Eli Lilly chronic kidney disease Phase I
Indianapolis, IN lilly.com
CLP-1004 Sorbent Therapeutics chronic kidney disease Phase I
(potassium channel modulator) Sunnyvale, CA sorbent.com
CTP-499 Concert Pharmaceuticals diabetic nephropathy Phase I
Lexington, MA concertpharma.com
INV-144 InVasc Therapeutics chronic kidney disease Phase II
(losartan/thioctic acid) Tucker, GA invasc.net
linagliptin Boehringer Ingelheim Pharmaceuticals diabetic nephropathy Phase III
Ridgefield, CT boehringer-ingelheim.com
Eli Lilly lilly.com
Indianapolis, IN
LY3016859 Eli Lilly diabetic nephropathy Phase I
Indianapolis, IN lilly.com
MP-146 Mitsubishi Tanabe Pharma chronic kidney disease Phase III
Osaka, Japan mt-pharma.co.jp
MR antagonist Eli Lilly chronic kidney disease Phase II
(LY2623091) Indianapolis, IN lilly.com
PF-00489791 Pfizer diabetic nephropathy Phase II
(PDE5 inhibitor) New York, NY pfizer.com
PF-04634817 Pfizer diabetic nephropathy Phase II
(CCR2/CCR5 receptor antagonist) New York, NY pfizer.com
Pyridorin™ NephroGenex diabetic nephropathy Phase II
pyridoxamine Rsch. Triangle Park, NC (Fast Track) nephrogenex.com
TGF-ß mAb Eli Lilly diabetic nephropathy Phase II
(LY2382770) Indianapolis, IN lilly.com
VTP-27999 Vitae Pharmaceuticals chronic kidney disease Phase I
(renin inhibitor) Fort Washington, PA vitaepharma.com
Medicines in Development Older Americans 2013 15

16. Medicines in Development for Older Americans
Chronic Obstructive Pulmonary Disease (COPD)
Product Name Sponsor Indication Development Phase
aclidinium bromide/formoterol Forest Laboratories chronic obstructive pulmonary Phase III
combination New York, NY disease (COPD) frx.com
AZD2115 AstraZeneca COPD Phase II
(MABA) Wilmington, DE astrazeneca.com
Pulmagen Therapeutics
Slough, United Kingdom
AZD5423 AstraZeneca COPD Phase II
(inhaled SGRM) Wilmington, DE astrazeneca.com
AZD7594 AstraZeneca COPD Phase I
(inhaled SGRM) Wilmington, DE astrazeneca.com
BCT197 Novartis Pharmaceuticals COPD Phase II
East Hanover, NJ novartis.com
bedoradrine MediciNova exacerbations of COPD Phase II
(MN-221) San Diego, CA medicinova.com
benralizumab AstraZeneca COPD Phase II
(anti-IL-5R mAb) Wilmington, DE astrazeneca.com
MedImmune medimmune.com
Gaithersburg, MD
BI-137882 Boehringer Ingelheim Pharmaceuticals COPD Phase I
Ridgefield, CT boehringer-ingelheim.com
BIO-11006 BioMarck Pharmaceuticals COPD Phase II
Durham, NC biomarck.com
Dulera® Merck COPD application submitted
mometasone/formoterol Whitehouse Station, NJ merck.com
fluticasone furoate/vilanterol/ GlaxoSmithKline COPD Phase I
umeclidinium combination Rsch. Triangle Park, NC gsk.com
formoterol/fluticasone propionate Mylan Specialty COPD Phase II completed
fixed-dose combination Basking Ridge, NJ mylanspecialty.com
glycopyrrolate Sunovion Respiratory Development COPD Phase II
(SUN-101) Marlborough, MA sunovion.com
GSK225629 GlaxoSmithKline COPD Phase I
(soluble epoxide hydrolase Rsch. Triangle Park, NC gsk.com
inhibitor)
16 Medicines in Development Older Americans 2013

17. Medicines in Development for Older Americans
Chronic Obstructive Pulmonary Disease (COPD)
Product Name Sponsor Indication Development Phase
GSK1325756 GlaxoSmithKline COPD Phase I
(CXCR2 chemokine receptor Rsch. Triangle Park, NC gsk.com
antagonist)
GSK2269557 GlaxoSmithKline COPD Phase I
(phosphoinositide 3 kinase Rsch. Triangle Park, NC gsk.com
inhibitor)
GSK961081 GlaxoSmithKline COPD Phase II
(muscarinic antagonist/beta2 Rsch. Triangle Park, NC gsk.com
agonist) Theravance theravance.com
South San Francisco, CA
losmapimod GlaxoSmithKline COPD Phase II
(oral p38 kinase inhibitor) Rsch. Triangle Park, NC gsk.com
MEDI-7814 AstraZeneca COPD Phase I
(anti-C5/C5a mAb) Wilmington, DE astrazeneca.com
MedImmune medimmune.com
Gaithersburg, MD
MEDI-8968 AstraZeneca COPD Phase II
(nati-IL-1R mAb) Wilmington, DE astrazeneca.com
MedImmune medimmune.com
Gaithersburg, MD
NVA237 Novartis Pharmaceuticals COPD Phase III
(glycopyrrolate inhalation) East Hanover, NJ novartis.com
olodaterol/tiotropium bromide Boehringer Ingelheim Pharmaceuticals COPD Phase III
fixed-dose combination Ridgefield, CT boehringer-ingelheim.com
OPC-6535 Otsuka America Pharmaceutical COPD Phase II
(tetomilast) Rockville, MD otsuka.com
PF-03715455 Pfizer COPD Phase I
(MAPK-14 inhibitor) New York, NY pfizer.com
PH-797804 Pfizer COPD Phase II
(p38 MAP kinase inhibitor) New York, NY pfizer.com
Prochymal™ Osiris Therapeutics COPD Phase II
remestemcel-L Columbia, MD (see also diabetes) osiris.com
PT001 Pearl Therapeutics COPD Phase II
(glycopyrrolate inhalation aerosol) Redwood City, CA pearltherapeutics.com
PT003 Pearl Therapeutics COPD Phase II
(glycopyrrolate/formoterol Redwood City, CA pearltherapeutics.com
inhalation aerosol)
Medicines in Development Older Americans 2013 17

18. Medicines in Development for Older Americans
Chronic Obstructive Pulmonary Disease (COPD)
Product Name Sponsor Indication Development Phase
PT005 Pearl Therapeutics COPD Phase II
(formoterol inhalation aerosol) Redwood City, CA pearltherapeutics.com
PUR118 Pulmatrix COPD Phase I
Lexington, MA pulmatrix.com
QMF149 Novartis Pharmaceuticals COPD Phase II
(indacaterol/mometasome East Hanover, NJ novartis.com
fixed-dose combination)
QVA149 Novartis Pharmaceuticals COPD Phase III
(glycopyrrolate/indacaterol East Hanover, NJ novartis.com
fixed-dose combination)
salbutamol dry-powder Teva Pharmaceutical COPD Phase II
inhalation North Wales, PA tevapharm.com
Striverdi Respimat™ Boehringer Ingelheim Pharmaceuticals COPD application submitted
olodaterol Ridgefield, CT boehringer-ingelheim.com
suvorexant Merck COPD Phase I completed
(dual orexin receptor antagonist) Whitehouse Station, NJ merck.com
TD-4208 Theravance COPD Phase II
(LAMA) South San Francisco, CA theravance.com
umeclidinium GlaxoSmithKline COPD Phase III
(muscarinic acetylcholine Rsch. Triangle Park, NC gsk.com
antagonist)
umeclidinium/vilanterol GlaxoSmithKline COPD application submitted
fixed-dose combination Rsch. Triangle Park, NC gsk.com
vilanterol GlaxoSmithKline COPD Phase III
(long-acting beta2 agonist) Rsch. Triangle Park, NC gsk.com
Theravance theravance.com
South San Francisco, CA
vilanterol/fluticasone furoate GlaxoSmithKline COPD application submitted
fixed-dose combination Rsch. Triangle Park, NC gsk.com
Theravance theravance.com
South San Francisco, CA -------------------------------------- -----------------------------------------
COPD (mortality claim) Phase III
gsk.com
theravance.com
18 Medicines in Development Older Americans 2013

19. Medicines in Development for Older Americans
Depression
Product Name Sponsor Indication Development Phase
ABT-436 AbbVie major depressive disorder Phase II
(selective vasopressin receptor North Chicago, IL abbvie.com
antagonist)
ALKS-5461 Alkermes major depressive disorder Phase II
(buprenorphine/samidorphan Waltham, MA alkermes.com
fixed-dose combination)
amitifadine Euthymics major depressive disorder Phase II/III
Cambridge, MA euthymics.com
ARA 290 Araim Pharmaceuticals depressive disorders Phase II
Ossining, NY araim.org
armodafinil Teva Pharmaceutical major depressive disorder Phase III
Tikvah, Israel tevapharm.com
AZD6765 AstraZeneca major depressive disorder Phase II
(NMDA receptor antagonist) Wilmington, DE astrazeneca.com
BCI-632 BrainCells major depressive disorder Phase I
(mGluR2/3 antagonist) San Diego, CA braincellsinc.com
BCI-838 BrainCells major depressive disorder Phase I
(mGluR2/3 antagonist) San Diego, CA braincellsinc.com
BMS-820836 Bristol-Myers Squibb major depressive disorder Phase II
(triple reuptake inhibitor) Princeton, NJ bms.com
brexpiprazole Otsuka Pharmaceutical adjunct therapy for major Phase III
(OPC-34712) Rockville, MD depressive disorder otsuka.com
Brintellix™ Lundbeck major depressive disorder application submitted
vortioxetine Deerfield, IL lundbeck.com
Takeda Pharmaceuticals International takeda.com
Deerfield, IL
cariprazine Forest Laboratories major depressive disorder Phase III
New York, NY frx.com
CX157 CeNeRx BioPharma major depressive disorder Phase II completed
(monoamine oxidase A inhibitor) Cary, NC cenerx.com
DSP-1053 Sunovion Pharmaceuticals depression Phase I
(serotonin uptake inhibitor) Marlborough, MA sunovion.com
Medicines in Development Older Americans 2013 19

20. Medicines in Development for Older Americans
Depression
Product Name Sponsor Indication Development Phase
edivoxetine Eli Lilly major depressive disorder Phase III
(LY2216684) Indianapolis, IN lilly.com
GLYX-13 Naurex major depressive disorder Phase II
Evanston, IL naurex.com
HT-2157 Dart NeuroScience major depressive disorder Phase I/II
(GALR3 antagonist) San Diego, CA dartneuroscience.com
JNJ-40411813 Janssen Research Development major depressive disorder with Phase II
(mGluR2 modulator) Raritan, NJ anxiety symptoms janssenrnd.com
levomilnacipran Forest Laboratories major depressive disorder application submitted
(F2695) New York, NY frx.com
lisdexamfetamine Shire major depressive disorder Phase III
Wayne, PA shire.com
lurasidone Sunovion Pharmaceuticals bipolar depression application submitted
Marlborough, MA sunovion.com
LY2940094 Eli Lilly major depressive disorder Phase II
Indianapolis, IN lilly.com
mifepristone Corcept Therapeutics psychotic major depression Phase III
Menlo Park, CA (Fast Track) corcept.com
MK-6096 Merck major depressive disorder Phase II
(orexin receptor 1/2 antagonist) Whitehouse Station, NJ merck.com
nefiracetam Neuren Pharmaceuticals major depressive disorder Phase II
Bethesda, MD post-stroke neurenpharma.com
NSI-189 Neuralstem major depressive disorder Phase I
(stimulating neurogenesis) Rockville, MD neuralstem.com
PNB01 PharmaNeuroBoost severe major depressive disorder Phase III
(citalopram/pipamperone Alken, Belgium pharmaneuroboost.com
fixed-dose combination)
RG1578 Roche major depression disorder Phase II
(mGluR2 modulator) Nutley, NJ roche.com
RG7090 Roche treatment-resistent depression Phase II
(mGluR5 antagonist) Nutley, NJ roche.com
RO4995819 Roche major depressive disorder Phase II
Nutley, NJ roche.com
20 Medicines in Development Older Americans 2013

21. Medicines in Development for Older Americans
Depression
Product Name Sponsor Indication Development Phase
SEP-228432 Sunovion Pharmaceuticals major depressive disorder Phase I
Marlborough, MA sunovion.com
SKL-DEP SK Biopharmaceuticals major depressive disorder Phase I
Seoul, South Korea skbp.com
tedatioxetine Lundbeck major depressive disorder Phase II
Deerfield, IL lundbeck.com
Takeda Pharmaceuticals International takeda.com
Deerfield, IL
TGBA01AD Fabre-Kramer Pharmaceuticals major depressive disorder Phase II
Houston, TX fabrekramer.com
Diabetes
Product Name Sponsor Indication Development Phase
11ß-HSD1 inhibitor Eli Lilly type 2 diabetes Phase II
(LY2523199) Indianapolis, IN lilly.com
AC-201 TWi Pharmaceuticals type 2 diabetes Phase II
Taipei, Taiwan twipharma.com
Afrezza® Mannkind type 1 diabetes, type 2 diabetes Phase III
insulin inhalation Valencia, CA mannkindcorp.com
albiglutide GlaxoSmithKline type 2 diabetes application submitted
Rsch. Triangle Park, NC (see also heart) gsk.com
aleglitazar Genentech type 2 diabetes Phase III
South San Francisco, CA gene.com
Roche roche.com
Nutley, NJ
alpha-1 antitrypsin (AAT) OmniBio Pharmaceuticals type 1 diabetes Phase I/II
Greenwood Village, CO omnibiopharma.com
AMG 151 Amgen type 2 diabetes Phase II
Thousand Oaks, CA amgen.com
anagliptin Kowa Research Institute type 2 diabetes Phase II
(DPP-4 inhibitor) Morrisville, NC kowaus.com
Medicines in Development Older Americans 2013 21

22. Medicines in Development for Older Americans
Diabetes
Product Name Sponsor Indication Development Phase
analog insulin-PH20 Halozyme type 1 diabetes, type 2 diabetes Phase II
San Diego, CA halozyme.com
ARI-2243 Arisaph Pharmaceuticals type 2 diabetes Phase I
(DPP-4 inhibitor) Boston, MA arisaph.com
BGP-15 N-Gene Research Laboratories type 2 diabetes Phase II
New York, NY ngene.us
BI-135585 Boehringer Ingelheim Pharmaceuticals type 2 diabetes Phase I
(11ß-HSD1 inhibitor) Ridgefield, CT boehringer-ingelheim.com
BIOD-123 Biodel type 1 diabetes Phase II
(ultra-rapid-acting recombinant Danbury, CT biodel.com
human insulin)
BIOD-125 Biodel type 1 diabetes Phase I completed
(ultra-rapid-acting recombinant Danbury, CT biodel.com
human insulin)
BIOD-238 Biodel diabetes Phase I
(ultra-rapid-acting recombinant Danbury, CT biodel.com
human insulin)
BIOD-250 Biodel diabetes Phase I
(ultra-rapid-acting recombinant Danbury, CT biodel.com
human insulin)
BMS-770767 Bristol-Myers Squibb type 2 diabetes Phase II
(11ßHSD inhibitor) Princeton, NJ bms.com
canagliflozin Janssen Research Development type 2 diabetes application submitted
Raritan, NJ janssenrnd.com
canagliflozin/metformin Janssen Research Development type 2 diabetes Phase III
extended-release formulation Raritan, NJ janssenrnd.com
canagliflozin/metformin Janssen Research Development type 2 diabetes application submitted
immediate-release formulation Raritan, NJ janssenrnd.com
canakinumab Novartis Pharmaceuticals type 2 diabetes Phase II/III
(ACZ885) East Hanover, NJ (see also arthritis) novartis.com
CAT 1004 Catabasis Pharmaceuticals type 2 diabetes Phase I
Cambridge, MA catabasis.com
22 Medicines in Development Older Americans 2013

23. Medicines in Development for Older Americans
Diabetes
Product Name Sponsor Indication Development Phase
cetilistat Norgine type 2 diabetes in clinically obese Phase II
Amsterdam, Netherlands patients norgine.com
CJC-1134-PC ConjuChem type 2 diabetes Phase II
Los Angeles, CA conjuchem.com
COV 096 Pfizer type 2 diabetes Phase I
(PF-04856883) New York, NY pfizer.com
dapagliflozin AstraZeneca type 2 diabetes application submitted
Wilmington, DE astrazeneca.com
Bristol-Myers Squibb bms.com
Princeton, NJ
dapagliflozin/metformin AstraZeneca type 2 diabetes Phase III
fixed-dose combination Wilmington, DE astrazeneca.com
Bristol-Myers Squibb bms.com
Princeton, NJ
DC-9703 Obio Pharmaceutical type 2 diabetes Phase I
Kowloon, Hong Kong obiopharma.com
diabetes medicine Eli Lilly diabetes Phase I
(biologic) Indianapolis, IN lilly.com
diabetes medicine Eli Lilly diabetes Phase I
(biologic) Indianapolis, IN lilly.com
diabetes medicine Eli Lilly diabetes Phase I
(biologic) Indianapolis, IN lilly.com
diabetes medicine Eli Lilly diabetes Phase I
(biologic) Indianapolis, IN lilly.com
diabetes medicine Eli Lilly diabetes Phase I
(NCE) Indianapolis, IN lilly.com
diabetes medicine Eli Lilly diabetes Phase I
(NCE) Indianapolis, IN lilly.com
DiaPep277® Andromeda Biotech type 1 diabetes Phase III
Yavne, Israel andromedabio.com
DS-7250 Daiichi Sankyo diabetes Phase I
(DGAT1 inhibitor) Parsippany, NJ dsi.com
Medicines in Development Older Americans 2013 23

24. Medicines in Development for Older Americans
Diabetes
Product Name Sponsor Indication Development Phase
DSP-8658 Sunovion Pharmaceuticals type 2 diabetes Phase I
(PPAR alpha/gamma agonist) Marlborough, MA (see also Alzheimer’s) sunovion.com
dulaglutide Eli Lilly type 2 diabetes Phase III
(LY2189265) Indianapolis, IN lilly.com
EGT-0001442 Theracos type 2 diabetes Phase II
(SGLT2 inhibitor) Marlborough, MA theracos.com
EGT-0001474 Theracos type 2 diabetes Phase I completed
(SGLT2 inhibitor) Marlborough, MA theracos.com
empagliflozin Boehringer Ingelheim Pharmaceuticals type 2 diabetes Phase III
(BI-10773) Ridgefield, CT boehringer-ingelheim.com
Eli Lilly lilly.com
Indianapolis, IN
empagliflozin/linagliptin Boehringer Ingelheim Pharmaceuticals type 2 diabetes Phase III
fixed-dose combination Ridgefield, CT boehringer-ingelheim.com
Eli Lilly lilly.com
Indianapolis, IN
empagliflozin/metformin Boehringer Ingelheim Pharmaceuticals type 2 diabetes Phase I
fixed-dose combination Ridgefield, CT boehringer-ingelheim.com
Eli Lilly lilly.com
Indianapolis, IN
emricasan Conatus Pharmaceuticals type 1 diabetes Phase I/II
San Diego, CA conatuspharma.com
enclomifene Repros Therapeutics type 2 diabetes in men with Phase II
The Woodlands, TX secondary hypogonadism reprosrx.com
fasiglifam Takeda Pharmaceuticals International type 2 diabetes Phase III
(TAK-875) Deerfield, IL takeda.com
GK1-399 Forest Laboratories type 2 diabetes Phase II
(glucokinase activator) New York, NY frx.com
glimepiride extended-release/ GlaxoSmithKline type 2 diabetes Phase I
metformin extended-release Rsch. Triangle Park, NC gsk.com
fixed-dose combination
glucagon-R antagonist Eli Lilly type 2 diabetes Phase II
(LY2409021) Indianapolis, IN lilly.com
GPR40 Bristol-Myers Squibb type 2 diabetes in clinical trials
Princeton, NJ bms.com
24 Medicines in Development Older Americans 2013